AVS Bio Appoints Jac Price as Chief Executive Officer to Expand Bioprocessing Platform
Norwich, Connecticut, July 18, 2023 – AVS Bio (the “Company”), the leading provider of specific pathogen free (“SPF”) products and services that support biologic development and manufacturing, is pleased to announce the appointment of Jac Price as Chief Executive Officer.
With over 25 years of executive leadership experience in the life sciences and biomedical testing industries, Mr. Price most recently served as SVP of Supply Chain & Manufacturing at Abcam and was previously SVP of Global Operations & Diagnostics at Beckman Coulter. In joining AVS Bio, Mr. Price brings a wealth of expertise and a proven track record of success in leading companies through periods of new product development and transformative growth.
Mr. Price expressed his enthusiasm for joining AVS Bio, stating, “The AVS Bio team has built an outstanding business to support its global customer base in the development and manufacturing of biologics that are critical to both human and animal health. I am excited to work with the talented team already in place and leverage their expertise to accelerate the development of new products and services and expand into new markets across diagnostics and immunology.”
Malcolm Little, a Director at AVS Bio and a Partner at Arlington Capital Partners, said, “Jac’s addition to AVS Bio as CEO is very exciting for the Company. His exceptional leadership skills, proven acquisition and integration expertise, and extensive experience across life sciences and diagnostics make him the perfect fit to lead the expansion of the AVS Bio platform alongside our existing management team.”
Deb Tosto, President of AVS Bio, added, “We are thrilled to welcome Jac to the AVS Bio family. With his arrival, we look forward to an even greater emphasis on innovation, research and development, and strategic partnerships that will enable us to expand our offerings to meet the evolving needs of our growing pharmaceutical customer base.”
About AVS Bio
Headquartered in Norwich, CT, AVS Bio is the leading global provider of specific pathogen free (“SPF”) eggs and adjacent laboratory products and services that support the development and manufacturing of vaccines, therapeutics, and other biologics used for human and animal health. Prior to its acquisition by Arlington Capital Partners and management, the Company operated as a subsidiary of Charles River Laboratories (NYSE:CRL). The Company currently employs ~250 employees across 20+ facilities in Connecticut, New York, Illinois, Missouri, and Europe.
For more information: www.avsbio.com
About Arlington Capital Partners
Arlington Capital Partners is a Washington, DC-based private equity firm that has managed approximately $7 billion in capital commitments. Arlington is focused on middle market investment opportunities in growth industries including healthcare, government services and technology, aerospace & defense, and business services and software. The firm’s professionals and network have a unique combination of operating and private equity experience that enable Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their company’s position as leading competitors in their field.
For more information: www.arlingtoncap.com
Malcolm Little & Mark Giragosian
Arlington Capital Partners
5425 Wisconsin Avenue, Suite 200
Chevy Chase, MD 20815